Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults

References

• Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 1999;34:65–72
   PubMed Web of Science ®Google Scholar
• Swartz MN. Cellulitis and subcutaneous tissue infections, In: Mandell GL, Bennett JE, Dolan R, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone Inc.; 2000. p. 1037–57
   Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Uncomplicated and complicated skin and skin structure infections – developing antimicrobial drugs for treatment. Draft Guidance July 1998. At: http://www.fda.gov/cder/guidance/index.htm [accessed: July 7, 2006]
   Google Scholar
• Elston DM. Optimal antibacterial treatment of uncomplicated skin and skin structure infections: applying a novel treatment algorithm. J Drugs Dermatol 2005;4(Suppl 6):S15–S19
   Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373–406
   PubMed Web of Science ®Google Scholar
• NPA™ Plus (National Prescription Audit Plus). IMS Health. April, 2006
   Google Scholar
• Physician Drug & Diagnosis Audit (PDDA) from Verispan, January 2006 – March 2006
   Google Scholar
• Nolen T. Comparative studies of cefprozil in the management of skin and soft-tissue infections. Eur J Clin. Microbiol Infect Dis 1994;13:866–71
   PubMed Web of Science ®Google Scholar
• Schatz BS, Karavokiros KT, Taeubel MA, et al. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Ann Pharmacother 1996;30:258–68
   PubMed Web of Science ®Google Scholar
• Wilson SE. The management of skin and skin structure infections in children, adolescents and adults: a review of empiric antimicrobial therapy. Int J Clin Pract 1998;52:414–7
   PubMed Web of Science ®Google Scholar
• Wiseman LR, Benfield P. Cefprozil: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs 1993;45:295–317
   PubMed Web of Science ®Google Scholar
• Tack KJ, Keyserling CH, McCarty J, et al. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. Antimicrob Agents Chemother 1997;41: 739–42
   PubMed Web of Science ®Google Scholar
• Bucko AD, Hunt BJ, Kidd SL, et al. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther 2002;24:1134–47
   PubMed Web of Science ®Google Scholar
• Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000;54:497–503
   PubMed Web of Science ®Google Scholar
• Zetola N, Francis JS, Nuermberger EL, et al. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5:275–86
   PubMed Web of Science ®Google Scholar
• King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309–17
   PubMed Web of Science ®Google Scholar
• Moran GJ, Amii RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005;11:928–30
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus – Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 1999;48:707–10
   PubMedGoogle Scholar
• Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128–32
   Google Scholar
• Omnicef® Prescribing Information. Abbott Laboratories ©2005. At: www.abbott.com [accessed July 7, 2006]
   Google Scholar
• Keflex® Prescribing Information. Advancis Pharmaceutical Corporation ©2005. At: http://www.advancispharm.com/products/keflex/ [accessed July 7, 2006]
   Google Scholar
• National Committee for Clinical Laboratory Standards, 2000. Performance standards for antimicrobial disk susceptibility tests; approved standard NCCLS document M2-A7 and 10th informational supplement (M100-S10[M2])
   Google Scholar
• National Committee for Clinical Laboratory Standards, 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-fifth edition, M7-A5 and 10th informational supplement (M100 S10[M7])
   Google Scholar
• Matilde-Sanchez MM, Chen X. Choosing the analysis population in non-inferiority studies: per-protocol or intent-to-treat. Statist Med 2006;25:1169–81
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S16 (ISBN 1–56238–588–7). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087–1898 USA, 2006
   Google Scholar
• Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004;23:123–7
   PubMed Web of Science ®Google Scholar
• Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004;139: 947–53
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman JC, Morrison M, et al.; for the Active Bacterial Core Surveillance Program of the Emerging Infections Program. Methicillin-resistant Staphylococcus aureus disease in three communities. New Engl J Med 2005;352:1436–44
   Google Scholar
• Chambers HF. Community-associated MRSA – resistance and virulence converge. New Engl J Med 2005;352:1485–7
   PubMed Web of Science ®Google Scholar
• Madaras-Kelly KJ, Arbogast R, Jue S. Increased therapeutic failure for cephalexin versus comparator antibiotics in the treatment of uncomplicated outpatient cellulitis. Pharmaco-therapy 2000;20:199–205
   Google Scholar